Moderna, Inc. has announced that five abstracts related to its investigational mRNA therapeutics will be presented at the upcoming 2025 International Congress of Inborn Errors of Metabolism (ICIEM). This significant event is scheduled to take place from September 2 to 6, 2025, at the Kyoto International Conference Center in Kyoto, Japan.
Among the accepted abstracts, Moderna will showcase three oral presentations and two poster presentations focusing on its research into propionic acidemia (PA), methylmalonic acidemia (MMA), and Glycogen Storage Disease Type 1a (GSD1a). Notably, this marks the first occasion that Moderna will present data specifically related to MMA and GSD1a at a scientific congress, highlighting the company’s commitment to advancing treatments for these rare metabolic disorders.
Details of Presentations
The presentations will cover various aspects of Moderna’s mRNA therapeutic programs, which aim to address significant metabolic challenges faced by patients. The specific details of the abstracts have not yet been released; however, the focus on PA, MMA, and GSD1a underscores the potential of mRNA technology in developing innovative treatments for inborn errors of metabolism.
These conditions, which affect the body’s ability to metabolize certain substances, can lead to severe health complications. By leveraging mRNA technology, Moderna aims to create targeted therapies that could improve patient outcomes and enhance quality of life.
Significance of the Congress
The International Congress of Inborn Errors of Metabolism is a premier event that gathers researchers, clinicians, and industry leaders from around the world. It serves as a platform for sharing the latest advancements in the field, fostering collaboration, and discussing the challenges and opportunities in treating metabolic disorders.
With increasing interest in the role of mRNA therapeutics, Moderna’s participation at ICIEM is poised to generate significant attention. As the company continues to push the boundaries of medical science, its presentations may provide valuable insights into the future of treatment options for rare diseases.
As Moderna prepares for this important gathering, the scientific community will be keenly observing the results and implications of their findings. The company’s ongoing research efforts in the realm of mRNA therapeutics could pave the way for transformative approaches in managing inborn errors of metabolism.